Glycated hemoglobin News and Research

RSS

Study: Electronic health records can improve care, outcomes in patients with type 2 diabetes

Use of electronic health records shows promise for improving care and outcomes in patients with type 2 diabetes, but still has considerable room for improvement, according to a new study in the journal Health Services Research.

30 Jan 2012

Diabetes may cause women to experience hearing loss as they age

Having diabetes may cause women to experience a greater degree of hearing loss as they age, especially if the metabolic disorder is not well controlled with medication, according to a new study from Henry Ford Hospital in Detroit.

27 Jan 2012

New biomarkers can predict risk of kidney failure in patients with diabetes

Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.

20 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Major health insurers prosper with expanding roles in Medicare, Medicaid

Meanwhile, a California study shows health care costs in that state are rising, while benefits are shrinking. Another study finds that coverage gaps can be disruptive to preventive care.

6 Jan 2012

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Obstacles people with type 2 diabetes face that prevent them from getting ultimate treatment

Eli Lilly and Company today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.

2 Dec 2011

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.

28 Nov 2011

Benefits of vitamin D-fortified yoghurt drink for people with diabetes

People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.

24 Nov 2011

Hemoglobin A1c fails to identify children with diabetes

In 2009, the American Diabetes Association (ADA) recommended that Hemoglobin A1c be exclusively used for the diagnosis of diabetes in children. The simple test measures longer-term blood sugar levels -- without requiring patients to fast overnight. However, a new U-M study has shown that these tests are not very accurate in children.

21 Nov 2011

NIH-funded project to discover biomarkers for type 2 diabetes

Arizona State University will lead a four-year, $5 million expanded initiative sponsored by the National Institutes of Health to discover proteins, or biomarkers, to help predict cardiovascular disease and to assess potential new treatments in people with type 2 diabetes.

2 Nov 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011

Endocrine Society releases clinical practice guideline on continuous glucose monitoring

Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations on settings where patients are most likely to benefit from continuous glucose monitoring.

12 Oct 2011

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Three randomized controlled trials published Online First today in Archives of Internal Medicine examine the effectiveness of behavioral and educational interventions for patients with poorly controlled diabetes.

11 Oct 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011